Author

V. S. Iyer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

F. Wermeling· 2 shared L. Jiang· 2 shared S. V. Boddul· 2 shared Y. Shen· 2 shared Z. Kasza· 2 shared B. Raposo· 1 shared D. P. Lane· 1 shared K. Ingelshed· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

9 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Wermeling

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CRISPR enriches for cells with mutations in a p53-related interactome, and this can be inhibited.

L. Jiang, K. Ingelshed, Y. Shen, S. V. Boddul, V. S. Iyer, Z. Kasza, S. Sedimbi, D. P. Lane, F. Wermeling

The paper shows that CRISPR enriches cells with p53-related mutations and demonstrates that transient p53 inhibition can suppress this effect.

bioRxiv · Mar 10, 2021 · PreprintCancer Biology

A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system

Y. Shen, L. Jiang, V. S. Iyer, B. Raposo, S. V. Boddul, Z. Kasza, F. Wermeling

This paper introduces a CRISPR-based assay to identify drug targets affecting hematopoietic cells by analyzing genotype enrichment in mixed CRISPR populations.

bioRxiv · Mar 8, 2021Immunology